A groundbreaking case report recently published in the May 2026 issue of Oncoscience sheds new light on the complexities of diagnosing combined hepatocellular-cholangiocarcinoma (cHCC-CCA), a rare and aggressive primary liver cancer subtype. Characterized by its unique blend of both hepatocellular carcinoma and cholangiocarcinoma within a single tumorous mass, cHCC-CCA presents profound diagnostic and therapeutic challenges that continue to puzzle clinicians and pathologists alike. This report is particularly significant as it offers a comprehensive pathological and clinical narrative of a patient whose tumor’s heterogeneous architecture complicated initial diagnosis and treatment planning.
The research, led by Dr. Faten Limaiem from Hospital Mongi Slim La Marsa in Tunisia, recounts the clinical journey of a 61-year-old male patient with a history of chronic hepatitis B, diabetes mellitus type 2, and hypertension. The patient presented with persistent right upper quadrant abdominal pain, prompting advanced imaging studies which revealed a heterogeneous liver mass displaying capsular retraction alongside marked enlargement of hilar lymph nodes. Notably, laboratory tests demonstrated elevated serum alpha-fetoprotein (AFP) levels, a biomarker typically associated with hepatocellular carcinoma. However, these clinical clues only partially captured the tumor’s multifaceted identity.
Initial diagnostic efforts, including computed tomography (CT)-guided biopsy, led clinicians to preliminarily classify the lesion as hepatocellular carcinoma. Such an initial assessment, however, belied the tumor’s true complexity. Post-surgical pathological examination of the resected tumor specimen revealed an intricate histological architecture: approximately 20% of the lesion consisted of hepatocellular carcinoma cells, while a predominant 80% was composed of cholangiocarcinoma elements. This finding unequivocally established the diagnosis of combined hepatocellular-cholangiocarcinoma.
The report highlights one of the primary obstacles in cHCC-CCA diagnosis—the intratumoral heterogeneity. Because different tumor regions harbor distinct cellular phenotypes, small biopsy samples may inadvertently sample only one component, thereby misrepresenting the tumor’s mixed nature. This highlights a critical limitation of preoperative biopsy, especially in tumors of notable histological diversity. The authors emphasize that comprehensive pathological evaluation, integrating surgical specimen analysis, remains indispensable for accurate diagnosis.
Immunohistochemical profiling was a cornerstone of the diagnostic confirmation process in this case. The hepatocellular carcinoma component expressed classical markers including Glypican-3, HepPar1, and AFP, all hallmark indicators of hepatocellular differentiation. Conversely, the cholangiocarcinoma component exhibited robust expression of cytokeratin 7 (CK7) and cytokeratin 19 (CK19), markers consistent with biliary epithelial lineage. This biphenotypic expression reinforces the pathogenetic complexity of cHCC-CCA and underscores the necessity for multi-marker panels in differential diagnosis.
Radiological imaging further complicated the clinical picture, as the tumor’s radiologic features were congruent with a cholangiocarcinoma-predominant lesion, consistent with the histologic predominance of cholangiocarcinoma cells found in the pathological specimen. Such overlaps in imaging features can obscure tumor classification efforts, particularly in the absence of integrative histological and molecular analyses. The report thus exemplifies the critical role of correlating radiologic findings with pathological data to refine diagnostic accuracy.
Therapeutic options for combined hepatocellular-cholangiocarcinoma remain severely limited due to the tumor’s rarity and biological heterogeneity. Currently, surgical resection stands as the only potentially curative approach. However, no standardized treatment protocols exist for cHCC-CCA to guide systemic therapy or adjuvant interventions. This diagnostic uncertainty and therapeutic ambiguity drive an urgent need for further research into molecular drivers, tumor microenvironment characteristics, and potential targeted therapies.
The case underscores the imperative for multidisciplinary management in dealing with cHCC-CCA. Integration of clinical insights, advanced imaging modalities, comprehensive histopathology, and detailed immunohistochemical workup is essential to improving diagnostic confidence and therapeutic decisions. Moreover, the mixed cellular phenotype demands that clinicians maintain a high index of suspicion when evaluating complex liver lesions, especially in patients with risk factors such as chronic viral hepatitis and metabolic comorbidities.
This publication also serves as a clarion call for enhanced awareness among the oncologic and pathological communities regarding the nuances of cHCC-CCA. Detailed dissemination of such case reports contributes to the collective understanding of this rare malignancy and helps propel progress toward more refined diagnostic algorithms and potentially novel treatment paradigms. The authors eloquently point out that while the literature is gradually expanding, concerted efforts to standardize classification and treatment remain urgently needed.
In conclusion, the report by Dr. Limaiem and colleagues pioneers a vital contribution to hepatobiliary oncology. It showcases not only the diagnostic intricacies posed by tumor heterogeneity in cHCC-CCA but also the overarching limitations of conventional biopsy methods. The findings underscore the paramount importance of thorough pathological examination post-resection. Future strides in this field will likely hinge upon integrative diagnostics combining molecular profiling with histology, aiming to unravel the enigmatic biology of these biphenotypic tumors.
The insights from this study poignantly illustrate that combined hepatocellular-cholangiocarcinoma is far more than a mere histological curiosity—it epitomizes the evolving challenge of liver cancer diagnosis in an era increasingly reliant on precision medicine. As the oncology community around the globe continues to grapple with such complex neoplasms, elucidating their molecular landscapes and clinical behaviors remains a top priority to ultimately improve patient outcomes.
This work stands as a testament to the crucial role of case study reports in advancing medical knowledge, highlighting rare but clinically important tumor entities. It further reminds us that in the intricate world of cancer diagnosis and treatment, a nuanced and multidisciplinary approach is often the key to unlocking therapeutic potential for patients afflicted with formidable malignancies such as combined hepatocellular-cholangiocarcinoma.
Subject of Research: People
Article Title: Combined hepatocellular-cholangiocarcinoma: A rare and challenging diagnostic entity- A case report
News Publication Date: 24 June 2026
Web References:
https://doi.org/10.18632/oncoscience.658
https://www.oncoscience.us/archive/v13/
Image Credits: © 2026 Limaiem et al. This is an open access article distributed under the Creative Commons Attribution License (CC BY 4.0).
Keywords: liver cancer, combined hepatocellular-cholangiocarcinoma, pathology, immunohistochemistry, case report
Tags: advanced imaging in liver tumor diagnosisalpha-fetoprotein biomarker in liver cancerchallenges in liver cancer pathologycHCC-CCA clinical presentationchronic hepatitis B and liver cancer riskcombined hepatocellular-cholangiocarcinoma diagnosisliver cancer imaging and biopsy challengesliver cancer with heterogeneous tumor architecturemixed hepatocellular and cholangiocarcinoma tumormultidisciplinary approach to liver cancer managementrare primary liver cancer case reporttherapeutic challenges in rare liver cancers